Antitope Announces EpiScreen™ Collaboration with Daiichi Sankyo to Analyze Immunogenicity in Therapeutic Antibodies
Antitope Ltd. ("Antitope") today announced a research collaboration with the Japanese multinational pharmaceutical company Daiichi Sankyo Company Limited ("Daiichi Sankyo") in which Antitope will apply its proprietary EpiScreen™ technology to analyze the immunogenicity of Daiichi Sankyo’s therapeutic monoclonal antibodies.
"We are very pleased to be working with Daiichi Sankyo whom we recognize as a world leader for development and commercialization of therapeutic antibodies," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "We look forward to assisting Daiichi Sankyo in selecting antibodies with low immunogenicity potential arising from their pioneering R&D programmes."
About Antitope
Antitope Ltd. is a privately-held Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology provides for preclinical analysis of the immunogenicity potential of therapeutic antibodies and proteins. Antitope's proprietary Composite Human Antibody™ technology results in humanized antibodies devoid of T cell epitopes. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk or contact:
Dr. Neil Butt
Business Development Director, Antitope Ltd.
Tel: +44 (0)1223 496190
About Daiichi Sankyo
In keeping with its vision of becoming a “Global Pharma Innovator,” the Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of customers in both developed and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model,” which will respond to market and customer diversity and optimize growth opportunities across the value chain.
For more information, please visit www.daiichisankyo.com